Erschienen in:
29.03.2017 | Review Article
Role of TIM-3 in ovarian cancer
verfasst von:
Y. Xu, H. Zhang, Y. Huang, X. Rui, F. Zheng
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 9/2017
Einloggen, um Zugang zu erhalten
Abstract
Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4+ and CD8+ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer.